Klimek, Ludger
Förster-Ruhrmann, Ulrike
Beule, Achim G.
Chaker, Adam M.
Hagemann, Jan
Klimek, Felix
Casper, Ingrid
Huppertz, Tilman
Hoffmann, Thomas K.
Dazert, Stefan
Deitmer, Thomas
Olze, Heidi
Strieth, Sebastian
Wrede, Holger
Schlenter, Wolfgang
Welkoborsky, Hans-Jürgen
Wollenberg, Barbara
Bergmann, Christoph
Cuevas, Mandy
Beutner, Caroline
Gröger, Moritz
Becker, Sven
Funding for this research was provided by:
Universitätsklinikum Tübingen
Article History
Received: 9 May 2022
Accepted: 10 May 2022
First Online: 28 July 2022
Conflict of interest
: B. Wollenberg has received honoraria and/or research grants from MSD, Sanofi, Astra Zeneca, Novartis, and BMS Adboard outside of this work. J. Hagemann has received grants from Novartis Pharma GmbH for lectures. A. Chaker conducts consulting services (e.g. Advisory Boards, DSMBs), lectures or other activities for Allergopharma, ALK-Abello, Astra Zeneca, GSK, HAL Allergy, Mundipharma, Nexter, Immunotek, Lofarma, SanofiGenzyme and Regeneron through; has received clinical trials fees or research funding through the Technical University of Munich from ALK, Allergopharma, Astra Zeneca, Bencard/Allergen Therapeutics, ASIT Biotech, GSK, Novartis, Roche, and Zeller AG, as well as research funding from the Federal Environment Agency of the Federal Republic of Germany, EIT Health, and DZL (BMBF). AMC has also received honoraria and reimbursement of travel expenses from Bayerisches Ärzteblatt, the German Society for Allergology and Clinical Immunology (DGAKI) and the European Academy of Allergy and Clinical Immunology. H. Olze has received honoraria and/or research grants from F. Hoffmann-La Roche Ltd, Sanofi-Aventis Deutschland GmbH, AstraZeneca GmbH, and GlaxoSmithKline GmbH & Co. KG. L. Klimek reports grants and/or honoraria from Allergopharma, MEDA/Mylan, HAL Allergie, ALK Abelló, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT Biotech, Lofarma, Allergy Therapeut., AstraZeneca, GSK, and Inmunotk, outside of those submitted Work; and membership in the following organizations: AeDA, DGHNO, German Academy for Allergology and Clinical Immunology, ENT-BV GPA, and EAACI. U. Förster-Ruhrmann has received lecture fees from Novartis, AstraZeneca, Sanofi, and GSK outside of the present work. S. Strieth reports grants from the German Research Foundation (DFG), Bonn, the Head and Neck Cancer Research Foundation, Wiesbaden, and Fresenius Kabi, Bad Hersfeld; grants and non-financial funding from MED-EL AG, Innsbruck; staff fees from Auris Medical, Basel, Merck Serono, Darmstadt, Otonomy, Inc., San Diego (USA), Sanofi Genzyme, Berlin, ALK-Abelló Arzneimittel, Hamburg, and Nordmark Arzneimittel, Uetersen; subsidy from Andreas Fahl Medizintechnik-Vertrieb, Cologne, Atos Medical, Troisdorf, and Tracoe Medical, Nieder-Olm; scholarships from Heimomed Heinze, Kerpen, and Bromepithetik, Heidelberg, outside of the submitted work. M. Cuevas has received honoraria from AstraZeneca, GSK, Sanofi and Novartis outside of this work. W. Schlenter, S. Becker, A.G. Beule, T. Deitmer, H.J. Welkoborsky, S. Dazert, T. Huppertz, T.K. Hoffmann, H. Wrede, C. Bergmann, F. Klimek and I. Casper have no conflicts of interest related to the present work.